Pharmacology of JNJ-42314415, a centrally active phosphodiesterase 10A (PDE10A) inhibitor: a comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotic drugs.

Autor: Megens AA; Janssen Research & Development, a Division of Janssen Pharmaceutica, NV Beerse, Belgium., Hendrickx HM, Hens KA, Fonteyn I, Langlois X, Lenaerts I, Somers MV, de Boer P, Vanhoof G

Publikováno v: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2014 Apr; Vol. 349 (1), pp. 138-54. Date of Electronic Publication: 2014 Jan 13.

Design, synthesis, and tripeptidyl peptidase II inhibitory activity of a novel series of (S)-2,3-dihydro-2-(4-alkyl-1H-imidazol-2-yl)-1H-indoles.

Autor: Breslin HJ; Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Welsh and McKean Roads, P.O. Box 776, Spring House, Pennsylvania 19477-0776, USA. HBreslin@prdus.jnj.com, Miskowski TA, Kukla MJ, Leister WH, De Winter HL, Gauthier DA, Somers MV, Peeters DC, Roevens PW

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2002 Nov 21; Vol. 45 (24), pp. 5303-10.